IP Library › Granted Patent US 9,631,184
Granted Patent B2
US 9,631,184 · App. 14/429,641 · Granted Apr 25, 2017

Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate

Inventor: Sang Jae Kim (Seoul, KR)
Assignee: GEMVAX & KAEL CO., LTD.
C12N9/1276A23L29/06A61K8/66A61K38/45A61K47/48246C07K14/485C07K14/52C07K16/46A23V2002/00A61K38/00A61K2800/10C07K2319/10C07K2319/21C07K2319/60C12Y207/07049
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,631,184
App. No.
14/429,641
Granted
Apr 25, 2017
Kind
B2
Abstract

The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 6, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 6, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Claims (22)

1. A conjugate comprising an isolated carrier peptide and an active ingredient, wherein the carrier peptide is 20 amino acids in length and consists of the amino acid sequence of any one of SEQ ID NOs:1-4.

2. The conjugate of claim 1 , wherein the isolated carrier peptide and the active ingredient are joined by a linker.

3. The conjugate of claim 1 , wherein the isolated carrier peptide and the active ingredient are joined via a non-covalent bond.

4. The conjugate of claim 1 , wherein the active ingredient is at least one selected from the group consisting of a protein, a nucleic acid, a peptide, lipid, a glycol-lipid, a mineral, a sugar, a nano-particle, a biological product, a contrast agent, a drug, and a chemical compound.

5. The conjugate of claim 1 , wherein the active ingredient is fluorescein isothiocyanate (FITC) or Green Fluorescent Protein (GFP).

6. The conjugate of claim 4 , wherein the contrast agent is selected from the group consisting of a radiopaque contrast agent, a paramagnetic contrast agent, a superparamagnetic contrast agent, and a CT contrast agent.

7. The conjugate of claim 6 , wherein the contrast agent comprises iron.

8. The conjugate of claim 6 , wherein the contrast agent comprises ferrocenecarboxylic acid.

9. A composition comprising the conjugate according to claim 1 as an active ingredient.

10. The composition of claim 9 , comprising 0.1 μg/mg to 1.0 mg/mg of the isolated carrier peptide.

11. The composition of claim 9 , wherein the composition is a pharmaceutical composition formulated for oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, in the bone marrow, epidural, or subcutaneous administration.

12. A conjugate comprising an isolated carrier peptide and an active ingredient, wherein the carrier peptide is 8 amino acids in length and consists of the amino acid sequence of SEQ ID NO: 6.

13. The conjugate of claim 12 , wherein the isolated carrier peptide and the active ingredient are joined by a linker.

14. The conjugate of claim 12 , wherein the isolated carrier peptide and the active ingredient are joined via a non-covalent bond.

15. The conjugate of claim 12 , wherein the active ingredient is at least one selected from the group consisting of a protein, a nucleic acid, a peptide, lipid, a glycol-lipid, a mineral, a sugar, a nano-particle, a biological product, a contrast agent, a drug, and a chemical compound.

16. The conjugate of claim 12 , wherein the active ingredient is fluorescein isothiocyanate (FITC) or Green Fluorescent Protein (GFP).

17. The conjugate of claim 15 , wherein the contrast agent is selected from the group consisting of a radiopaque contrast agent, a paramagnetic contrast agent, a superparamagnetic contrast agent, and a CT contrast agent.

18. The conjugate of claim 17 , wherein the contrast agent comprises iron.

19. The conjugate of claim 17 , wherein the contrast agent comprises ferrocenecarboxylic acid.

20. A composition comprising the conjugate according to claim 12 as an active ingredient.

21. The composition of claim 20 , comprising 0.1 μg/mg to 1.0 mg/mg of the isolated carrier peptide.

22. The composition of claim 20 , wherein the composition is a pharmaceutical composition formulated for oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, in the bone marrow, epidural, or subcutaneous administration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2015
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 036028/0395 →
Priority Claims (4)
KR 10-2012-0104144 · Sep 19, 2012 · national
KR 10-2012-0109216 · Sep 28, 2012 · national
KR 10-2013-0017046 · Feb 18, 2013 · national
KR 10-2013-0017169 · Feb 18, 2013 · national
Continuity (1)
Related Publication 20160002613A1 · Jan 7, 2016